Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA

Jorge E. Cortes, Timothy Hughes, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna G. Turkina, Sarah Hurwicz Kogut, Ana Paula Torres Cardoso, Monali Sura, Giuseppe Saglio

Blood (2022) 140 (Supplement 1): 195–197.

https://doi.org/10.1182/blood-2022-167177

Published: 2022

Journal Articles

Results of a Single Center Survey on Vaccination Against COVID-19 in Patients with Chronic Myeloid Leukemia

Ekaterina Yu. Chelysheva, Anna Petrova, Oleg A. Shukhov, Margarita Gurianova, Anastasiya Bykova, Irina Nemchenko, Nikolay Tsyba, Alina V. Kokhno, Anna G. Turkina

Blood (2021) 138 (Supplement 1): 4604.

https://doi.org/10.1182/blood-2021-150226

Published: 2021

Journal Articles

The 15 Year Long-Term Survival of Patients with Chronic Myeloid Leukaemia from 35 Regions of Russian Federation: A Follow up of a Multicenter Observation Study Eutos Osp Initiated By European Leukemia NET

Blood (2021) 138 (Supplement 1): 5035.

https://doi.org/10.1182/blood-2021-151371

Published: 2021

Journal Articles

PF-114 in Patients Failing Prior Tyrosine Kinase-Inhibitor Therapy Including BCR::ABL1 T315I

Blood (2021) 138 (Supplement 1): 1482.

https://doi.org/10.1182/blood-2021-150120

Published: 2021

Journal Articles

The First Results of Asciminib Therapy in Highly Pretreated Chronic Myeloid Leukemia Patients Under the Managed Access Program (MAP) in Russian Federation

Anna G. Turkina, Oleg A. Shukhov, Elza Lomaia, Elena V. Morozova, Anna Petrova, Ekaterina Yu. Chelysheva, Tamara Chitanava, Julia J. Vlasova, Irina Nemchenko, Anastasiya Bykova, Margarita Gurianova, Andrey Zaritsky

Blood (2021) 138 (Supplement 1): 1483.

https://doi.org/10.1182/blood-2021-145712

Published: 2021

Journal Articles

Humoral Immunity and Adverse Events after Vaccination Against COVID-19 By a Vector Based Vaccine Sputnik V in Patients with Chronic Myeloid Leukemia

Ekaterina Yu. Chelysheva, Anna Petrova, Oleg A. Shukhov, Margarita Gurianova, Anastasiya Bykova, Irina Nemchenko, Nikolay Tsyba, Dmitry S. Tikhomirov, Anna G. Turkina

Blood (2021) 138 (Supplement 1): 4599.

https://doi.org/10.1182/blood-2021-152701

Published: 2021

Journal Articles

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

Blood (2021) 138 (Supplement 1): 310.

https://doi.org/10.1182/blood-2021-152561

Published: 2021

Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Blood (2020) 136 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2020-143816

Published: 2020

Journal Articles

The Role of BCR-ABL Levels Fluctuations and Loss of Deep Molecular Response after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia in the Prospective Trial RU-SKI

Anna Petrova, MD, Ekaterina Yu. Chelysheva, MD PhD, Oleg A. Shukhov, MD PhD, Anastasiya Bykova, MD, Irina Nemchenko, MD PhD, Olga Pospelova, MD, Margarita Gurianova, MD, Nikolay Tsyba, MD PhD, Tatiana I. Ionova, Prof., Anna G. Turkina, Prof., MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-141798

Published: 2020

Journal Articles

ENESTop 5-Year Update: Durability of Treatment-Free Remission Following Second-Line Nilotinib and Exploratory Analysis of Molecular Response Regain after Nilotinib Re-Initiation in Patients with Chronic Myeloid Leukemia

Francois-Xavier Mahon, MD PhD, Nelma D Clementino, MD, Mikhail Fominykh, MD, Jeffrey H. Lipton, MD PhD, Anna G. Turkina, Prof., MD, Beatriz Moiraghi, MD, Franck E Nicolini, MDPhD, Naoto Takahashi, MD PhD, Tomasz Sacha, MDPhD, Dong-Wook Kim, MD, Rafik Fellague-Chebra, MD, Ranjan Tiwari, MSc, Catherine Bouard, Timothy P. Hughes, MDMBBS,FRACP,FRCPA

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-136250

Published: 2020

Journal Articles

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Blood (2019) 134 (Supplement_1): 1638.

https://doi.org/10.1182/blood-2019-127951

Published: 2019

Journal Articles

The Impact of Comorbidity on Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Results of the RU-SKI Trial

Tatyana Ionova, PhD Professor, Tatiana Nikitina, PhD, Natalia Porfirieva, Anna Petrova, MD, Ekaterina Yu. Chelysheva, MD PhD, Oleg A. Shukhov, MD PhD, Anastasiya Bykova, MD, Galina Gusarova, MD PhD, Irina Nemchenko, MD PhD, Nikolay Tsyba, MD PhD, Anna G. Turkina, Prof., MD

Blood (2019) 134 (Supplement_1): 2925.

https://doi.org/10.1182/blood-2019-122041

Published: 2019

Journal Articles

Changes in the Multipotent Stromal Mesenchymal Cells from the Bone Marrow of the Patients with Hematological Diseases in Debut and after the Treatment

Irina N. Shipounova, PhD, Nataliya A. Petinati, MD PhD, Nina J. Drize, PhD, Aminat A. Magomedova, MD PhD, Ekaterina A. Fastova, MD, Sergey K. Kravchenko, MD PhD, Ekaterina Yu. Chelysheva, MD PhD, Oleg A. Shukhov, MD PhD, Anna G. Turkina, Prof., MD, Elena N. Parovichnikova, MD PhD, Valery G. Savchenko, MD PhD academician

Blood (2019) 134 (Supplement_1): 5014.

https://doi.org/10.1182/blood-2019-123396

Published: 2019

Journal Articles

Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database

Blood (2019) 134 (Supplement_1): 498.

https://doi.org/10.1182/blood-2019-124430

Published: 2019

Journal Articles

On a Long Way to the Treatment Free Remisson: The Results of the Long-Term Observation of the Chronic Myeloid Leukemia Patients in Russian Part of EUTOS Population-Based Study

Olga V. Lazareva, PhD, Ekaterina Yu. Chelysheva, MD PhD, Anton Kulikovsky, Olga Senderova, Valentina Pepeliaeva, Sergey Meresiy, Alexander S. Luchinin, MD, Galina Milutina, Lubov Gavrilova, Ludmila Avdeeva, Dolgorzhap Dasheeva, Olga Vinogradova, MD PhD, Sergei M. Kulikov, PhD, Anna G. Turkina, Prof., MD

Blood (2019) 134 (Supplement_1): 5902.

https://doi.org/10.1182/blood-2019-131430

Published: 2019

Journal Articles

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Blood (2018) 132 (Supplement 1): 790.

https://doi.org/10.1182/blood-2018-99-116803

Published: 2018

Journal Articles

Kinetics of the Leukemic Clone in Patients with Chronic Myeloid Leukemia during Pregnancy

Ekaterina Chelysheva, MD PhD, Jane Apperley, MB ChB MD, Elisabetta Abruzzese, Dong-Wook Kim, MD PhD, Konstantin Kotlyarchuk, Oleg Shukhov, MD PhD, Anna G Turkina, Prof., MD

Blood (2018) 132 (Supplement 1): 4254.

https://doi.org/10.1182/blood-2018-99-115984

Published: 2018

Journal Articles

Chronic Myeloid Leukemia Diagnosed during Pregnancy: Therapy, Outcomes and Follow-up

Ekaterina Chelysheva, MD PhD, Elisabetta Abruzzese, Delphine Rea, MD, Dong-Wook Kim, MD PhD, Khamida Kazakbaeva, MD, Sukhrob Saliev, Konstantin Kotlyarchuk, Evgenia Polushkina, Roman Shmakov, MD PhD, Julia Chabaeva, Sergei M. Kulikov, PhD, Anna G Turkina, Prof., MD

Blood (2018) 132 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2018-99-115983

Published: 2018

Journal Articles

Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Interim Results of Russian Prospective Multicenter Trial RU-SKI

Anna Petrova, MD, Ekaterina Chelysheva, MD PhD, Oleg Shukhov, MD PhD, Anastasiya Bykova, MD, Galina Gusarova, MD PhD, Irina Nemchenko, MD PhD, Nikolay Tsyba, MD PhD, Anna G Turkina, Prof., MD, Tatiana Nikitina, PhD, Natalia Porfirieva, Anna Zinkovskaya, Tatiana Ionova, DSc

Blood (2018) 132 (Supplement 1): 3023.

https://doi.org/10.1182/blood-2018-99-113360

Published: 2018

Journal Articles

Social Parameters Are Independent Predictors for Survival in Chronic Myeloid Leukemia

Sergei M. Kulikov, PhD, Anna G Turkina, Prof., MD, Anton Kulikovsky, Olga Lazareva, PhD, Sergey Kutsev, Prof., MD, PhD, Elza Lomaia, MD, Andrey Zaritskey, MD PhD, Anatoly Golenkov, MDProf, Tatiana Pospelova, MD PhD, Satokhin Yuri, MD PhD, Tatiana Konstantinova, MD PhD, Elena N. Parovichnikova, MD PhD, Valeriy G. Savchenko, MD PhD

Blood (2018) 132 (Supplement 1): 1735.

https://doi.org/10.1182/blood-2018-99-114700

Published: 2018

NARROW

Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA

Results of a Single Center Survey on Vaccination Against COVID-19 in Patients with Chronic Myeloid Leukemia

The 15 Year Long-Term Survival of Patients with Chronic Myeloid Leukaemia from 35 Regions of Russian Federation: A Follow up of a Multicenter Observation Study Eutos Osp Initiated By European Leukemia NET

PF-114 in Patients Failing Prior Tyrosine Kinase-Inhibitor Therapy Including BCR::ABL1 T315I

The First Results of Asciminib Therapy in Highly Pretreated Chronic Myeloid Leukemia Patients Under the Managed Access Program (MAP) in Russian Federation

Humoral Immunity and Adverse Events after Vaccination Against COVID-19 By a Vector Based Vaccine Sputnik V in Patients with Chronic Myeloid Leukemia

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

The Role of BCR-ABL Levels Fluctuations and Loss of Deep Molecular Response after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia in the Prospective Trial RU-SKI

ENESTop 5-Year Update: Durability of Treatment-Free Remission Following Second-Line Nilotinib and Exploratory Analysis of Molecular Response Regain after Nilotinib Re-Initiation in Patients with Chronic Myeloid Leukemia

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

The Impact of Comorbidity on Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Results of the RU-SKI Trial

Changes in the Multipotent Stromal Mesenchymal Cells from the Bone Marrow of the Patients with Hematological Diseases in Debut and after the Treatment

Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database

On a Long Way to the Treatment Free Remisson: The Results of the Long-Term Observation of the Chronic Myeloid Leukemia Patients in Russian Part of EUTOS Population-Based Study

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Kinetics of the Leukemic Clone in Patients with Chronic Myeloid Leukemia during Pregnancy

Chronic Myeloid Leukemia Diagnosed during Pregnancy: Therapy, Outcomes and Follow-up

Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Interim Results of Russian Prospective Multicenter Trial RU-SKI

Social Parameters Are Independent Predictors for Survival in Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only